Kailera Therapeutics, Inc. (KLRA)
12.58
+0.43
(+3.54%)
USD |
NASDAQ |
Nov 03, 16:00
12.58
0.00 (0.00%)
After-Hours: 17:50
Kailera Therapeutics Enterprise Value : 668.36M for Nov. 2, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 02, 2026 | 668.36M |
| October 30, 2026 | 760.39M |
| October 29, 2026 | 831.68M |
| October 28, 2026 | 832.98M |
| October 27, 2026 | 795.39M |
| October 26, 2026 | 748.73M |
| October 23, 2026 | 759.10M |
| October 22, 2026 | 813.54M |
| October 21, 2026 | 768.17M |
| October 20, 2026 | 764.28M |
| October 19, 2026 | 575.04M |
| October 16, 2026 | 551.70M |
| October 15, 2026 | 611.33M |
| October 14, 2026 | 485.60M |
| October 13, 2026 | 489.49M |
| October 12, 2026 | 562.07M |
| October 09, 2026 | 598.37M |
| October 08, 2026 | 389.68M |
| October 07, 2026 | 458.38M |
| October 06, 2026 | 497.26M |
| October 05, 2026 | 498.56M |
| October 02, 2026 | 440.23M |
| October 01, 2026 | 523.19M |
| September 30, 2026 | 573.74M |
| September 29, 2026 | 518.00M |
| Date | Value |
|---|---|
| September 28, 2026 | 534.85M |
| September 25, 2026 | 547.17M |
| September 24, 2026 | 646.33M |
| September 23, 2026 | 795.39M |
| September 22, 2026 | 751.32M |
| September 21, 2026 | 647.62M |
| September 18, 2026 | 756.50M |
| September 17, 2026 | 768.17M |
| September 16, 2026 | 739.65M |
| September 15, 2026 | 836.87M |
| September 14, 2026 | 875.76M |
| September 11, 2026 | 900.38M |
| September 10, 2026 | 1.026B |
| September 09, 2026 | 1.017B |
| September 08, 2026 | 1.223B |
| September 04, 2026 | 1.197B |
| September 03, 2026 | 1.134B |
| September 02, 2026 | 1.148B |
| September 01, 2026 | 1.221B |
| August 31, 2026 | 1.090B |
| August 28, 2026 | 1.195B |
| August 27, 2026 | 1.495B |
| August 26, 2026 | 1.484B |
| August 25, 2026 | 1.394B |
| August 24, 2026 | 1.237B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Twist Bioscience Corp. | 8.014B |
| Prime Medicine, Inc. | 819.88M |
| GRAIL, Inc. | 5.204B |
| Arrowhead Pharmaceuticals, Inc. | 8.182B |
| Oncolytics Biotech, Inc. | 46.19M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -111.31M |
| Total Expenses (Quarterly) | 111.31M |
| EPS Diluted (Quarterly) | -0.8587 |
| Earnings Yield | -13.44% |